HDAC9 and cystic fibrosis: In the present study, we demonstrate the utility of SAHA (suberoylanilide hydroxamic acid, a HDAC inhibitor), in modulating innate and adaptive immune responses by controlling NFκB-IL-8-mediated neutrophil-chemotaxis, and T-reg activation, which may control the progression of chronic CF-lung disease by balancing the inflammatory response.